Holzer R B
Medizinische Universitätspoliklinik, Inselspital, Bern.
Ther Umsch. 1990 Oct;47(10):795-808.
Plasmodium falciparum is resistant to proguanil, chloroquine and pyrimethamine/sulfadoxine (Fansidar) in many parts of the world. It can be assumed that in the future resistance to mefloquine and quinine will also increase. This will have important consequences for the recommended schemes for drug prophylaxis. No new drugs suitable for prophylaxis will be on the market in the near future. Neither the combination of mefloquine with pyrimethamine/sulfadoxine (Fansimef) nor the new drug halofantrine will solve the impending problems. It has to be accepted that no absolute protection against malaria infection can be guaranteed by the presently available drugs. In regions with low transmission no permanent prophylaxis but only a standby therapy is recommended. Moreover, personal protection against mosquitoes with pyrethrum-impregnated bed-nets and repellents will gain importance.
恶性疟原虫在世界许多地区对氯胍、氯喹和乙胺嘧啶/磺胺多辛(Fansidar)产生了耐药性。可以推测,未来对甲氟喹和奎宁的耐药性也会增加。这将对推荐的药物预防方案产生重要影响。近期内不会有适合预防的新药上市。甲氟喹与乙胺嘧啶/磺胺多辛的组合(Fansimef)以及新药卤泛群都无法解决即将出现的问题。必须认识到,目前可用的药物无法保证对疟疾感染提供绝对保护。在传播率低的地区,不建议进行长期预防,而只推荐备用疗法。此外,使用除虫菊酯浸渍蚊帐和驱蚊剂进行个人防蚊将变得更加重要。